Medical Crossfire™ Pearls
Incorporating New Medication Paradigms into ADHD Therapy (Series: I - IV)
Chairman
David W. Goodman, M.D.
Assistant Professor,
Johns Hopkins Univ School of Medicine, Dept of Psychiatry and Behavioral Sciences
Johns Hopkins at Green Spring Station
Baltimore, MD
Panelist
Tony Rostain, MD, MA
Professor, Psychiatry and Pediatrics Director of Education, Dept of Psychiatry University of Pennsylvania Health System Philadelphia, PA |
Statement of Need
Developing an effective treatment plan for children and adolescents with ADHD can be challenging and requires significant input and buy-in from the family and school personnel; clinicians need to be able to effectively recognize and involve the necessary participants in the treatment of these children. Co-morbid conditions can complicate management and caregivers should be able to recognize these disorders and incorporate their management. Even with the variety of medications that are available for treatment, ADHD can still lead to short-and long-term problems in school and home life.
Understanding the use of stimulants and when to change to another stimulant or to non-stimulants in the treatment of ADHD is important for the clinician that manages ADHD. A non-stimulant has recently been approved for co-administration with stimulant medications with offers more treatment options for the physician and patient—especially if the stimulant is not working effectively alone. More research about long-term effects of these medications and the management of co-morbid diagnoses is becoming available. Because of the difficulty in management and expanding knowledge database, clinicians need continuing education to continue to improve their management of patients with ADHD.
Target Audience
This educational activity is designed for physicians, pediatricians, and other healthcare professionals interested in mental health.
Learning Objectives
Series 1
- Describe the burden of ADHD and the impairment associated with this condition in adolescents and adults
- Differentiate the clinical symptoms of ADHD across the lifespan
Series 2
- Understand how to recognize and manage the presence of co-morbid conditions in people with ADHD
- Utilize an algorithm for clinical assessment and diagnosis of ADHD in children and adults
Series 3
- Recognize the safety and efficacy of available pharmacologic and non-pharmacologic treatments for ADHD
- Describe the role of adjunctive medications in the treatment of ADHD
Series 4
- Develop a comprehensive, individualized, and evidence-based treatment plan that combines pharmacological and behavioral strategies to improve outcomes for children and adolescents with ADHD
Faculty Disclosure and Declarations
David W. Goodman, M.D.: Research grants for Shire Plc. Consultant for Shire Plc, McNeil, Thompson Reuters, Clinical Global Advisors, and Otsuka Pharmaceuticals. Received Honoraria from WebMD, Medscape, Temple University, and Neuroscience Education Institute. Royalties for MBL Communications.
Tony Rostain, MD, MA: Consultant for Shire Plc and Ortho-McNeil-Janssen Scientific Affairs.
Support Statement
This activity is supported by an independent medical educational grant from Shire.